Hydroxychloroquine in nonhospitalized adults with early covid-19: A randomized trial

Annals of Internal Medicine

Volumn 173, Issue 8, 2020, Pages 623-631

  Skipper, Caleb P ^a   Pastick, Katelyn A ^a   Engen, Nicole W ^a   Bangdiwala, Ananta S ^a   Abassi, Mahsa ^a   Lofgren, Sarah M ^a   Williams, Darlisha A ^a   Okafor, Elizabeth C ^a   Pullen, Matthew F ^a   Nicol, Melanie R ^a   Nascene, Alanna A ^a   Hullsiek, Kathy H ^a   Cheng, Matthew P ^b   Luke, Darlette ^c   Lother, Sylvain A ^d   MacKenzie, Lauren J ^d   Drobot, Glen ^d   Kelly, Lauren E ^e   Schwartz, Ilan S ^f   Zarychanski, Ryan ^d   McDonald, Emily G ^b   Lee, Todd C ^b   Rajasingham, Radha ^a   Boulware, David R ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Fairview Pharmacy Services LLC   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Karolinska Institutet   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; ANTIMALARIAL AGENT;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; COVID-19 TESTING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VISUAL ANALOG SCALE; BETACORONAVIRUS; CORONAVIRUS INFECTION; MIDDLE AGED; MULTICENTER STUDY; PANDEMIC; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; VIRUS PNEUMONIA;

ADULT; ANTIMALARIALS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; OUTPATIENTS; PANDEMICS; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 85089156211     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M20-4207     Document Type: Article

References (25)

1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. [PMID: 32150618] doi:10.1093/cid/ciaa237
2. Pastick KA, Okafor EC, Wang F, et al. Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis. 2020;7:ofaa130. [PMID: 32363212] doi:10.1093/ofid/ofaa130
3. Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. [PMID: 32387409] doi:10.1016/j.tmaid.2020 .101738
4. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 382:2411-2418. [PMID: 32379955] doi:10.1056/NEJMoa2012410
5. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020. [PMID: 32445440] doi:10.1056/NEJMoa2007764
6. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-1578. [PMID: 32423584] doi:10 .1016/S0140-6736(20)31022-9
7. Lother SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Study protocol for a pragmatic randomizedcontrolled trial. Can J Anaesth. 2020. [PMID: 32383125] doi:10 .1007/s12630-020-01684-7
8. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in falsenegative rate of reverse transcriptase polymerase chain reactionbased SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173:262-7. [PMID: 32422057] doi:10.7326/M20-1495
9. Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: A narrative review. Ann Intern Med. 2020;172:726-734. [PMID: 32282894] doi:10.7326/M20-1301
10. Council of State and Territorial Epidemiologists. Interim-20-ID-01: Standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19). Accessed at www.cste.org/resource/resmgr/2020ps/Interim-20-ID-01_COVID-19 .pdf on 20 April 2020.
11. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. [PMID: 32492293] doi:10.1056/NEJMoa 2016638
12. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: The desperate search for effectiveness. Clin Pharmacol Ther. 2020. [PMID: 32344449] doi:10.1002/cpt.1874
13. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. [PMID: 31078660] doi:10.1016/j.jbi.2019.103208
14. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:245-246. [PMID: 32134909] doi:10.15585/mmwr.mm6909e1
15. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). February 2020. Accessed at www.who.int/docs/default-source/coronaviruse/who-china -joint-mission-on-covid-19-final-report.pdf on 9 March 2020.
16. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50. [PMID: 10866439]
17. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24. [PMID: 10697061]
18. Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv. Preprint posted online 15 July 2020. doi:10.1101/2020.07.15.20151852
19. World Health Organization. Q & A : Hydroxychloroquine and COVID-19. 19 June 2020. Accessed at www.who.int/news-room/q-a -detail/q-a-hydroxychloroquine-and-covid-19 on 19 June 2020.
20. Kaptein SJF, Jacobs S, Langendries L, et al. Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine. bioRxiv. Preprint posted online 19 June 2020. doi:10.1101/2020.06.19.159053
21. Park SJ, Yu KM, Kim YI, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020;11. [PMID: 32444382] doi:10.1128/mBio.01114-20
22. Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in nonhuman primates. Research Square. Preprint posted online 6 May 2020. doi:10.21203/rs.3.rs-27223/v1
23. McMichael TM, Currie DW, Clark S, et al; Public Health-Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med. 2020;382:2005-2011. [PMID: 32220208] doi:10.1056/NEJMoa2005412
24. Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER: Deprescribing guidance for hydroxychloroquine drug interactions in olderadults.JAmGeriatrSoc.2020.[PMID:32441771]doi:10.1111/jgs .16623
25. World Health Organization. Global surveillance for human infection with coronavirus disease (COVID-19). 20 March 2020. Accessed at www.who.int/publications-detail/global-surveillance-for-human -infection-with-novel-coronavirus-(2019-ncov) on 20 March 2020.